Optimized Flomoxef Dosing Strategy for Extended-Spectrum Beta-Lactamase-Producing Bacteria, Based on Pooled Pharmacokinetic and Pharmacodynamic Analysis
Open Access
- 14 October 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1297
Abstract
Background: Flomoxef exhibits antibacterial activity against extended-spectrum beta-lactamase (ESBL)-producing bacteria and is a potential alternative to carbapenems. However, its pharmacokinetic (PK) characteristics remain unclear, and the appropriate minimum inhibitory concentration (MIC) breakpoint for flomoxef remains controversial. This study aimed to develop a flomoxef PK model using pooled meta-analysis and to evaluate various dosing regimens for ESBL-producing bacterial infections. Methods: Flomoxef concentration data were systematically collected from PubMed and J-STAGE. PK modeling of flomoxef was performed using the collected serum concentration data with NONMEM 7.5. Patient characteristics were examined as covariates for clearance and volume of distribution. For stochastic PK/pharmacodynamic (PD) simulation, the probability of attaining the PK/PD target {70% free time above the MIC [fT > MIC]} was calculated. The target MIC was determined by systematically reviewing flomoxef susceptibility data for ESBL-producing bacteria across different regions. Results: The population PK analysis included 39 adult patients [mean age, 58.2 years; mean body weight, 52.7 kg; and mean creatinine clearance (CLcr), 44.1 mL/min]. In the PK model, CLcr was incorporated as a covariate of flomoxef clearance. A visual predictive check and goodness-of-fit plots demonstrated relatively good stability and predictive performance of the final model. For the PD evaluation, the target MIC was set at 4 µg/mL based on the systematically collected susceptibility data for ESBL-producing bacteria. PK/PD breakpoints for dosing regimens of 1 g twice daily (2 g/day) in typical patients with CLcr = 10 mL/min, 1 g three times daily (3 g/day) in patients with CLcr = 30 mL/min, and 1 g four times daily (4 g/day) with 3 h-infusion in patients with CLcr = 60 and 90 mL/min achieved the target MIC. Conclusions: Based on the stochastic PK/PD simulation results, prolonged-infusion regimens may more effectively cover isolates with a target MIC of 4 µg/mL than short-duration infusion regimens in typical patients with normal renal function (CLcr = 60 or 90 mL/min). However, clinical studies in various scenarios including severe infections are needed to identify the relationship between PK/PD results and clinical efficacy since our findings are based solely on simulation.Keywords
Funding Information
- Japan Society for the Promotion of Science (25K18652)
This publication has 21 references indexed in Scilit:
- International consensus recommendations for the use of prolonged‐infusion beta‐lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases PharmacistsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection ModelPharmaceutical Research, 2021
- Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainmentJournal of Infection and Chemotherapy, 2020
- In vitro activity of flomoxef against extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella pneumoniae in KoreaDiagnostic Microbiology and Infectious Disease, 2019
- In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase–producing EnterobacteriaceaeDiagnostic Microbiology and Infectious Disease, 2016
- Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective studyInternational Journal of Antimicrobial Agents, 2015
- Clinical and microbiologic characteristics of adult patients with recurrent bacteraemia caused by extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniaeClinical Microbiology and Infection, 2015
- In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in ChinaInternational Journal of Antimicrobial Agents, 2015
- Flomoxef showed excellent in vitro activity against clinically important gram-positive and gram-negative pathogens causing community- and hospital-associated infectionsDiagnostic Microbiology and Infectious Disease, 2015
- Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programmingComputer Methods and Programs in Biomedicine, 2004